Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

Fig. 1

MAP17 upregulation occurs during lung tumourigenesis and is preferentially detected in lung adenocarcinomas. a Representative images of MAP17-stained lung tumour samples. b MAP17 mRNA expression in non-tumour (Normal), adenocarcinoma (ADC) and squamous cell carcinoma (SCC) samples from the TCGA Lung Cancer cohort. c MAP17 promoter and gene methylation in non-tumour and NSCLC samples (See Additional file 1: Table S2). Observed methylation changes (log2 ratio). Statistically significant differences (adjusted p-value < 0.05) of methylation levels with respect to those of the control (non-tumour) group were considered. The upper schematic represents the main location of probes for promoter or gene analysis. Below are comparative values of expression

Back to article page